STAT+: Bristol’s novel treatment for psoriasis meets study goals, beats rival Amgen drug
Bristol Myers Squibb said Tuesday that an oral drug designed to treat psoriasis differently from currently approved medicines demonstrated superiority to placebo and a competing drug from Amgen.
